These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

465 related items for PubMed ID: 19165083

  • 1. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.
    Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.
    AIDS; 2009 Feb 20; 23(4):455-60. PubMed ID: 19165083
    [Abstract] [Full Text] [Related]

  • 2. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, Si-Mohamed A, Piketty C.
    HIV Med; 2008 Oct 20; 9(9):765-70. PubMed ID: 18651855
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
    AIDS Rev; 2009 Oct 20; 11(1):17-29. PubMed ID: 19290031
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
    Garrido C, de Mendoza C, Alvarez E, García F, Morello J, Garcia S, Ribera E, Rodríguez-Novoa S, Gutierrez F, Soriano V, Sinres Team.
    AIDS Res Hum Retroviruses; 2012 Feb 20; 28(2):156-64. PubMed ID: 21457126
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.
    J Med Virol; 2012 Dec 20; 84(12):1869-75. PubMed ID: 23080489
    [Abstract] [Full Text] [Related]

  • 15. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B, Blum L, Collin G, Damond F, Peytavin G, Leleu J, Matheron S, Chêne G, Brun-Vézinet F, Descamps D, ANRS HIV-2 Co5 Cohort.
    AIDS; 2008 Oct 01; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract] [Full Text] [Related]

  • 16. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P, ANRS AC11 Resistance Group.
    Int J Antimicrob Agents; 2013 Jul 01; 42(1):42-7. PubMed ID: 23562640
    [Abstract] [Full Text] [Related]

  • 17. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
    Salgado M, Toro C, Simón A, Garrido C, Blanco F, Soriano V, Rodés B.
    J Clin Virol; 2009 Oct 01; 46(2):173-5. PubMed ID: 19625211
    [Abstract] [Full Text] [Related]

  • 18. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A, Van Baelen K, van Lelyveld SF, Schipper PJ, Stuyver LJ, Wensing AM, Nijhuis M.
    J Antimicrob Chemother; 2010 Nov 01; 65(11):2300-4. PubMed ID: 20736234
    [Abstract] [Full Text] [Related]

  • 19. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants.
    Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, Matsushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A, Fujiwara T.
    Antiviral Res; 2008 Nov 01; 80(2):213-22. PubMed ID: 18625269
    [Abstract] [Full Text] [Related]

  • 20. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Santos JR, Buzón MJ, Martínez-Picado J, Alvarez-Tejado M, Clotet B, Ruiz L, Paredes R.
    Antiviral Res; 2010 Dec 01; 88(3):281-6. PubMed ID: 20883724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.